Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial
- PMID: 37497730
- DOI: 10.55563/clinexprheumatol/eonoj3
Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial
Abstract
Objectives: The aim was to evaluate the ability of baseline multi-biomarker disease activity (MBDA) score to discriminate between patients with rheumatoid arthritis (RA) in remission who are at high risk versus low risk of relapse after TNF-inhibitor (TNFi) tapering.
Methods: The study is a post-hoc analysis of patients who completed the Spacing of TNFi injections in Rheumatoid ArthritiS Study (STRASS), a multicentre 18-month equivalence randomised controlled study, of TNFi tapering in RA patients in remission, and had baseline serum samples available for MBDA testing. The primary endpoint of this study was the ability of the baseline MBDA score to predict relapse at any time during the 18 months following initiation of TNFi tapering. Secondary endpoints were the ability of baseline MBDA score to predict TNFi discontinuation at Month 18, and structural damage progression on x-rays assessed by the change in total van der Heijde-modified Sharp score from baseline to month 18.
Results: 64 and 73 patients were included in the spacing (S)-arm and maintenance (M)-arm, respectively. In the M-arm, the mean MBDA score at baseline was higher among patients who relapsed during the 18-month follow-up than those who did not relapse: 32.5 compared to 27.2 (p=0.053) whereas no difference in the MBDA score was observed in the S-arm between patients who relapsed or not 27 compared to 26.2 (p=0.57) 13 patients (21.3%) of the S-arm were able to discontinue TNFi, for which the predictive value of the MBDA score was low (AUC=0.560). Radiographic progression in both arms, although low (n=9) was not correlated with the MBDA score at baseline with a poor discriminative value in both arms (AUC=0.558).
Conclusions: In our study MBDA score in baseline was not predictive of relapse, discontinuation of TNFi in patients with long-standing RA patients tapering TNFi.
Similar articles
-
A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003. Rheumatology (Oxford). 2017. PMID: 28339738 Clinical Trial.
-
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018. PLoS One. 2018. PMID: 29791439 Free PMC article. Clinical Trial.
-
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.Scand J Rheumatol. 2019 Jan;48(1):9-16. doi: 10.1080/03009742.2018.1464206. Epub 2018 Jul 9. Scand J Rheumatol. 2019. PMID: 29985080 Clinical Trial.
-
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3. Cochrane Database Syst Rev. 2019. PMID: 31125448 Free PMC article.
-
Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis.Rheumatology (Oxford). 2023 Jun 1;62(6):2048-2059. doi: 10.1093/rheumatology/keac715. Rheumatology (Oxford). 2023. PMID: 36575983 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical